Aim Systematic evidence on the prevalence and clinical outcome of transthyretin
amyloidosis (ATTR) is missing. We explored:(i) the prevalence of cardiac amyloidosis in …

Introduction Significant advances in the treatment of transthyretin (ATTR) amyloidosis has
led to an evolving understanding of the epidemiology of this condition. This systematic …

Background: Exercise capacity is related to mortality and morbidity in heart failure (HF)
patients. Determinants of exercise capacity in transthyretin cardiac amyloidosis (ATTR-CA) …

Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin
amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart …

Importance Cardiopulmonary exercise testing (CPET) has an established role in the
assessment of patients with heart failure. However, data are lacking in patients with …

Background The clinical value of cardiopulmonary exercise testing (CPET) in cardiac
amyloidosis (CA) is uncertain. Due to the growing prevalence of the disease and the current …

Aims Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) experience reduced
functional capacity. We evaluated changes in functional capacity over extensive follow-up …

Patients with CA displayed worse non-exertional CPET performance compared to non-CA
HF patients, which was associated with rehospitalization. Differences between correlations …

Cardiac amyloidosis (CA) is a myocardial disease characterized by extracellular amyloid
infiltration throughout the heart, resulting in increased myocardial stiffness, and restrictive …

The aim of this study is to evaluate the prognostic value of cardiopulmonary testing (CPET)
in a cohort of patients with transthyretin cardiac amyloidosis (ATTR-CA). ATTR-CA is …